A summary overview of the new, direct, target-specific oral anticoagulants

South African Family Practice

 
 
Field Value
 
Title A summary overview of the new, direct, target-specific oral anticoagulants
 
Creator Muntingh, G. L.
 
Subject — oral anticoagulants; target-specific; mechanism; clinical; pharmacokinetics
Description In the past 10 years or so, many alternatives to warfarin have been developed the first being the novel oral anticoagulants (NOAC) or better referred to as direct oral anticoagulants (DOAC) or target-specific oral anticoagulants (TSOAC). These drugs have some definite advantages and disadvantages that should be clear to physicians before prescribing any of them for patients. Many clinical trials have provided definitive information about the efficacy and safety of DOACs, yet many physicians remain sceptical about prescribing these drugs due to lack of answers to real world questions. The concerns are directed towards appropriate patient selection (the choice should be made according to age, renal function, compliance, cost, clinical condition, intake of other drugs), the mechanism of switching between agents, how these drugs affect routine laboratory tests and when monitoring is needed. Knowledge of other drugs that interact with the DOAC and management of severe bleeding will be reviewed and recommendations will be given to all of these concerns.
 
Publisher AOSIS
 
Contributor
Date 2016-08-04
 
Type info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Peer-reviewed Article —
Format application/pdf
Identifier 10.4102/safp.v58i4.4508
 
Source South African Family Practice; Vol 58, No 4 (2016): July/August; 22-25 2078-6204 2078-6190
 
Language eng
 
Relation
The following web links (URLs) may trigger a file download or direct you to an alternative webpage to gain access to a publication file format of the published article:

https://safpj.co.za/index.php/safpj/article/view/4508/5373
 
Coverage — — —
Rights Copyright (c) 2016 G.L. Muntingh https://creativecommons.org/licenses/by/4.0
ADVERTISEMENT